Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorWomen and Infants Hospital of Rhode Island
About this trial
The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.
Eligibility criteria
Qualifiers
18 years of age or older
undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder
Disqualifiers
cisgender male individuals
neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.)
known allergy and/or contraindication to methenamine hippurate
currently already taking methenamine hippurate at the time of the procedure
Trial design
Treatments tested in this trial
- Methenamine Hippurate
- Typically prescribed oral antibiotic prophylaxis
Treatment groups
164 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov